## Business Summary

Aethlon Medical is a medical technology company primarily focused on research and development (R&D) of a specialized device called the Hemopurifier. This device is designed to act as an external filter, similar to a kidney dialysis machine, removing harmful elements like viruses and particles related to cancer directly from the patient’s blood. Currently, the company does not earn significant revenue from commercial product sales because the device is still undergoing rigorous clinical trials to prove its safety and effectiveness. The business model relies heavily on securing government grants, entering into specialized research contracts, and raising capital from investors to fund its expensive development process. If the device achieves regulatory approval, its customers would be medical institutions, hospitals, and potentially government health systems, mainly operating within the United States and other developed markets.

---

## Business Model Risk

The most significant near-term risk is regulatory failure or delays. Since the company’s valuation hinges on the successful outcome of its clinical trials and eventual approval by agencies like the FDA, a negative or stalled trial result could immediately devalue years of investment. Historically, small biotech companies often face unexpected complications during trials, forcing them to halt progress. A related near-term concern is financing; R&D requires constant, high funding, and Aethlon must repeatedly secure capital, often by issuing new stock, which reduces the value of existing shares. The main long-term risk involves market competition and product viability. Even if the Hemopurifier is approved, competing medical advancements—such as new drugs or gene therapies—might emerge that treat the same diseases more effectively or cheaply, thereby limiting the market position and potential earnings of Aethlon’s device. These threats are a major cause for concern as they directly endanger the company's ability to transition from a research entity to a profitable commercial operation.

---

## Company History

This is a detailed history of Aethlon Medical, Inc. (AEMD), explaining its journey from a startup to a publicly traded medical technology company.

***

### Aethlon Medical, Inc. (AEMD): A History Lesson

#### The Company's Foundation and Core Goal

1.  **Inception (1999) and Founding Vision:** Aethlon Medical was founded in San Diego in 1999 with the goal of creating an entirely new way to fight life-threatening diseases.
2.  **The Core Problem to Solve:** The company recognized that the body's natural defense system can be overwhelmed or blocked by disease factors circulating in the blood, such as harmful viruses and tiny, destructive particles released by tumors called "exosomes."
3.  **The Goal:** The business was founded to develop an innovative "immunotherapeutic device" that would act like an external liver or a super-dialysis machine, cleaning the blood to rapidly remove these harmful elements and, in doing so, help "augment the body's natural immune defenses."

#### The Innovative Solution: The Hemopurifier

4.  **The Breakthrough Technology:** Their flagship product is the **Aethlon Hemopurifier$^{\circledR}$**, a "first-in-class" medical device designed to filter and purify the blood outside the body, similar to how a dialysis machine works for kidney failure.
5.  **How It Works Simply:** Blood is circulated out of the patient, passes through the Hemopurifier—which contains a specialized filter material (a proprietary "lectin-based technology")—that selectively binds and captures the dangerous circulating viruses and cancer-promoting exosomes. The cleansed blood is then returned to the patient.
6.  **Dual Application:** This single technology is designed to address two major areas of unmet need: (1) advanced or metastatic cancer, where tumor-secreted exosomes weaken the immune system and promote disease spread, and (2) life-threatening infectious diseases that lack effective antiviral drug treatments.

#### Key Milestones and Tailwinds (The Winds at Their Back)

7.  **FDA "Breakthrough Device" Designation:** A major advantage (a tailwind) for the company was receiving this special status from the U.S. Food and Drug Administration (FDA) for the Hemopurifier in both its cancer and viral applications. This designation is given to technologies that offer a more effective treatment for life-threatening diseases and helps expedite the device's development and review process.
8.  **Government Endorsement and Funding (DARPA):** Aethlon gained significant credibility and a financial boost by completing multiple milestones under a contract with the Defense Advanced Research Projects Agency (DARPA). This program validated the Hemopurifier's ability to capture high-threat viruses like MERS-CoV, demonstrating its potential as a broad-spectrum defense countermeasure against biological threats.
9.  **Global Recognition from a Crisis:** The device gained worldwide attention and was named one of **Time Magazine's 25 Best Inventions of 2014** after it was used to treat the Ebola virus during the West African outbreak, highlighting its potential in emergency viral defense.
10. **Adapting to Emerging Threats (COVID-19 and Long COVID):** The company quickly pivoted its research during the COVID-19 pandemic to investigate the Hemopurifier's potential to remove the SARS-CoV-2 virus and its spike protein. More recently, they have collaborated on preclinical research supporting the device's potential use in addressing the factors involved in Long COVID.

#### Challenges and Headwinds (The Obstacles They Faced)

11. **Navigating the Clinical and Regulatory Path:** As a developer of a novel medical device, the company constantly faces the lengthy, complex, and expensive process of conducting human clinical trials and obtaining final market approval from the FDA, which is a major financial and operational headwind.
12. **Trial Enrollment Speed:** A challenge in running clinical studies, such as the one for COVID-19, was initially finding and enrolling patients who met very specific criteria. The company addressed this by successfully lobbying the FDA to approve an amendment to the study protocol, which eliminated the requirement for patients to already be receiving dialysis, thereby broadening eligibility and potentially accelerating enrollment.
13. **Financial Sustainability:** Like many early-stage biotech companies focused heavily on research and development (R&D) before a product is widely commercialized, Aethlon has dealt with a lack of consistent revenue, resulting in financial headwinds like negative income and margins. They have responded strategically by implementing significant operating expense reductions to enhance long-term sustainability.
14. **Current Status and Focus:** Aethlon is currently advancing its lead program, the Hemopurifier, through clinical trials for cancer patients in Australia and continuing its research into viral diseases and new areas like Long COVID. They continue to focus on proving the device's safety and effectiveness to move toward commercialization and fulfilling their mission of transforming how life-threatening diseases are treated.

---

## Moat Analysis

The moat of Aethlon Medical, Inc. (AEMD) is based on a highly specific, patented medical technology targeting a new area of therapeutic intervention, coupled with significant regulatory advantages. Since the company is primarily in the clinical stage, its moat is centered on its intellectual property and the unique biological target of its device.

Here is an analysis of AEMD's competitive advantages and potential for a sustainable moat:

### Aethlon Medical's Moat and Differentiation

1.  **Unique Technology and Product Differentiation (The Core Moat)**
    *   **"First-in-Class" Mechanism:** The company's lead product, the Hemopurifier, is a "first-in-class" extracorporeal (outside the body) blood purification device. It is designed to specifically bind and remove cancer-promoting **extracellular vesicles (EVs, or exosomes)** and life-threatening **enveloped viruses** from a patient's bloodstream.
    *   **Proprietary Resin:** Its unique action is achieved through a proprietary, patented, plant-derived **lectin-based affinity resin** contained within a disposable cartridge, which targets mannose-rich surfaces on the EVs and viral proteins.
    *   **Differentiation from Competitors:** Most existing blood purification competitors focus on general adsorption, filtration, or dialysis for toxins, inflammatory mediators, or kidney failure. The Hemopurifier is distinct because it is an immunotherapy device that uses a specific bio-separation technique to address the underlying disease mechanisms of cancer and viral infections (like Long COVID) by removing the material that suppresses the body's immune system.

2.  **Intellectual Property (IP) Protection**
    *   **Patent Protection:** A solid moat is being built with a growing portfolio of international patents, with protection for new applications like Long COVID extending as far as 2042. This extensive patent life creates a significant barrier to entry, making it difficult for a competitor to develop and commercialize a device with the same unique mechanism of action.

3.  **Special Position in the Market and Pricing Power**
    *   **Breakthrough Device Designation:** The Hemopurifier holds a U.S. FDA Breakthrough Device Designation for both advanced cancer and life-threatening viral infections. This designation accelerates the regulatory review and adoption process, offering a significant time-to-market advantage and validation in areas of critical unmet need.
    *   **Pricing Power:** While the company is not fully commercialized, a successful device in a high-need, high-cost market like advanced cancer or critical care is likely to command premium pricing. The potential to combine with and enhance the effectiveness of multi-million dollar cancer drugs (like anti-PD-1 agents) could give the company significant pricing power.

4.  **Customer Stickiness and Recurring Revenue**
    *   **"Razor-and-Blade" Model:** The device's use in multiple "sessions" (e.g., three treatments per week in a trial) suggests a high-margin, **recurring revenue** business model where the initial machine is the "razor" and the proprietary, disposable Hemopurifier cartridge is the "blade" that must be purchased for every patient treatment.
    *   **High Switching Costs for Hospitals:** Once a hospital invests in the equipment, integrates the device into its critical care unit, and trains its specialized staff on the complex protocols, switching to a competitor's system would involve high financial and logistical costs, creating a high level of customer stickiness.

5.  **Investment in R&D and Displacement Risk**
    *   **Growth Driver:** The company's existence and unique position were established by its early, visionary research on the role of exosomes in disease years ago. The entire company is currently an R&D operation, focused on proving its technology in clinical trials for multiple indications like oncology, Long COVID, and organ transplantation.
    *   **Ease of Displacement:** The company is an early-stage, capital-constrained company, which makes it vulnerable to displacement by a competitor with more capital. However, the unique, long-term **patent protection (IP moat)** and the **Breakthrough Device Designation** are the primary defenses against being simply displaced. A larger company would likely have to acquire Aethlon or innovate a completely different, non-infringing technology, as they cannot easily copy the protected, proprietary resin.
    *   **Constant Innovation:** The medical device market is built on continuous innovation. Aethlon must continue to invest in R&D to expand the Hemopurifier's approved uses (e.g., Long COVID, organ transplant) and demonstrate clinical efficacy to maintain its edge and realize the full potential of its technology.

---

## Catalyst Analysis

Aethlon Medical, Inc. (AEMD) is a clinical-stage medical device company whose primary focus is advancing its Hemopurifier® technology. The key catalysts for the stock price revolve around clinical development, regulatory milestones, and strategic cost management.

### Near-Term Catalysts (6-12 Months)

1.  **Australian Oncology Trial Progress:** The completion of patient treatments in the ongoing Australian oncology trial is expected by late 2025 or early 2026. Positive data, particularly concerning the device's safety and optimal dosing, could drive stock price movement.
2.  **Clinical Trial Data Release:** The company recently announced that its Hemopurifier showed changes in tumor-related indicators (extracellular vesicles and microRNAs) in the first three patients of the Australian trial. Further safety data and biological observations from the Data Safety Monitoring Board (DSMB) review of the second cohort are a near-term catalyst.
3.  **Strategic Cost Reduction:** Management’s strategy in the Q1 2026 earnings call highlighted a 32% reduction in operating expenses, largely by cutting payroll and reducing legal fees. This move, including conserving up to \$1 million by focusing solely on the Australian trial, helps extend the cash runway and shows fiscal responsibility.
4.  **Upcoming Financial Update:** The release of fiscal Q2 2026 financial results and the associated conference call (scheduled for November 12, 2025) will provide an update on the balance sheet and clinical progress, which can influence stock sentiment.

### Long-Term Catalysts (1+ Year)

1.  **Australian Regulatory Approval Pathway:** A key goal mentioned by management is to use the data from the Australian trial to facilitate a potential Premarket Approval (PMA) or a future efficacy trial in Australia.
2.  **Long COVID Clinical Development:** The Hemopurifier has promising preclinical data showing it can remove extracellular vesicles implicated in Long COVID, with management actively pursuing regulatory approval in this area. The issuance of new U.S. and European patents for treating Long COVID and COVID-19-associated coagulopathy (CAC) strengthens their long-term intellectual property in infectious disease.
3.  **FDA Breakthrough Device Designation:** The Hemopurifier holds a U.S. FDA Breakthrough Device Designation for both specified oncology and viral indications, which may expedite its development and review process, representing a significant long-term milestone.
4.  **Strategic Partnerships:** Management has repeatedly emphasized the crucial need for securing additional capital and forming strategic partnerships to fund the next stages of clinical trials and commercialization. Successful partnerships or licensing deals would be a major long-term catalyst.

---

## Management Record

Based on an analysis of public information, here is an investor-relevant review of the management of Aethlon Medical, Inc. (AEMD).

### Current Management: James B. Frakes (CEO & CFO)

1.  **Current CEO & Dual Role:** James B. Frakes was appointed permanent Chief Executive Officer and a director on October 3, 2024, after serving as Interim CEO since November 2023. He maintains a dual role as both the Chief Executive Officer and Chief Financial Officer.
2.  **Long-Tenured Insider Background:** Mr. Frakes is a long-term company veteran, having joined Aethlon Medical in January 2008 and serving as its Chief Financial Officer since September 2010. His professional background includes over 30 years of public company experience, including CFO roles at four other public companies.
3.  **Experienced Leadership Team:** The broader management team is considered experienced, with an average tenure of 3.4 years, while the Board of Directors has an average tenure of 8 years. Key scientific management includes Chief Medical Officer Steven LaRosa, M.D., who has a strong clinical background, including previous Phase III clinical trial experience and work on the only FDA-approved sepsis agent.

### Past Management and Executive Changes

4.  **Recent CEO Change & Executive Streamlining:** Mr. Frakes replaced Charles J. Fisher, Jr., M.D., who departed in November 2023. Frakes explicitly stated that the previous CEO's departure and two other senior executive terminations over the past year were part of an effort to **streamline operations and significantly reduce operating costs**, demonstrating a focus on financial discipline.
5.  **Previous CEO's Tenure (Dr. Fisher):** Dr. Fisher served as CEO from October 2020 to November 2023, succeeding Dr. Timothy Rodell. Dr. Fisher's departure in late 2023 included a separation agreement with a 12-month cash severance and accelerated equity vesting.

### Management Performance and Track Record

6.  **Historical Shareholder Value:** The company's long-term stock performance indicates a severe inability to deliver sustained shareholder value; an investor who bought $1,000 worth of stock at the 1998 IPO would have a near-total loss today. Annual stock performance has been highly volatile, with steep declines in most recent years.
7.  **Performance Delivery (Frakes' Early Tenure):** Under Frakes' recent interim leadership, he claimed that the company made "more progress advancing in the clinic with our product this period than in any quarter since I've been with Aethlon." This statement suggests a recent operational turn, focusing resources to advance the core product.
8.  **Compensation vs. Performance:** An investor should note that the CEO's total compensation, while average for companies of similar size, increased while the company remains unprofitable. The company continues to report a net loss and is noted to be "quickly burning through cash."

### Future Strategy and Vision

9.  **Core Vision:** The company's central mission remains the development of the **Hemopurifier**, a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections.
10. **Key Strategic Focus:** The Hemopurifier has received a U.S. FDA **"Breakthrough Device"** designation for certain advanced or metastatic cancer treatments. The current management's stated strategy includes initiating a Phase 1 safety, feasibility, and dose-finding trial of the Hemopurifier in patients with solid tumors in India.
11. **Analyst and Financial Outlook:** The company is pre-revenue, with analysts forecasting no revenue for the immediate future (2026-2028), reflecting the early clinical stage. The consensus rating from analysts is generally **"Hold,"** underscoring the high-risk, high-reward nature of its clinical-stage technology.

---

## Management Incentive

Based on the analysis of Aethlon Medical, Inc.'s (AEMD) public filings, primarily the 2024 Form 10-K/A and Definitive Proxy Statements (DEF 14A), the management's incentives show a **low degree of direct alignment** with shareholder value creation.

### Management Incentive and Compensation Analysis

**1. Insider Ownership by Managers and Directors (Indicator: Higher the Better)**

*   **Low Apparent Insider Ownership:** The precise aggregate beneficial ownership percentage for all executive officers and directors as a group is not immediately clear from the search results, but the general context and small individual share counts (in relation to total outstanding shares) suggest a **low ownership percentage**.
*   **Weak Alignment Signal:** Low insider ownership means management's personal wealth is less tied to the company's stock price, which reduces their direct financial incentive to act solely in the long-term interest of the common shareholders.

**2. Executive Compensation Structure**

*   **Heavy Reliance on Fixed/Discretionary Pay:** The compensation structure is heavily weighted toward base salary and cash compensation, as opposed to performance-based equity. For a pre-commercial stage company, the total compensation for named executive officers in fiscal year 2024 is substantial, which may be perceived as high fixed cost given the company's limited revenue.
*   **Lack of Performance-Based Metrics:** The company explicitly states that, as a "pre-commercial stage company" with limited revenue, it **does not use net income (loss) as a performance measure** in its executive compensation program. This removes a key financial metric that would otherwise link pay directly to fundamental business success.
*   **Equity Awards:** Executive officers and directors receive stock options and Restricted Stock Units (RSUs), which *do* provide some alignment by increasing in value with the stock price. However, no new equity-based *incentive* awards were approved for the Named Executive Officers in the fiscal year ended March 31, 2024, which limits the forward-looking incentive component for that period.
*   **Director Compensation:** Non-employee directors receive a significant annual board retainer fee (e.g., $40,000 for a director, plus additional fees for committee chairs), which is paid in cash, common stock, or a combination, with the allocation determined by the Board.

### Conclusion on Incentive Alignment

*   **Incentivized to Line Their Own Pockets (Risk):** The compensation structure presents a higher risk of management being incentivized to prioritize their own pockets due to the high component of fixed, non-performance-based cash compensation, and the stated absence of net income/loss as a compensation metric.
*   **Weak Link to Shareholder Returns:** Because the company is pre-commercial, the performance element is weak or non-existent, meaning executives still receive a high salary even if clinical/business milestones are missed, or the stock price declines.
*   **Mitigating Factor:** The use of stock and options for both executives and directors provides a structural alignment, as its value only increases with a rise in the stock price, though the overall effectiveness is diminished by the apparently low total insider ownership and high fixed pay.

---

## Price History

The price history and current technical analysis for Aethlon Medical, Inc. (AEMD) reveal a highly volatile stock trading near its yearly lows, with mixed technical signals.

1.  **Proximity to 52-Week Low:** Using a recent closing price of approximately $4.19 and a reported 52-week low of $3.10, the stock is currently trading around **35.16%** above its 52-week low. Other sources indicate the stock's current price is very close to a higher 52-week low (e.g., $4.23 or $4.40), underscoring its extremely low trading range.

2.  **Technical Analysis Assessment:** Technical ratings for AEMD are generally **bearish** or a "Strong Sell" based on an analysis of moving averages and other key indicators, suggesting a falling trend.

3.  **Oversold Condition:** Despite the overall negative trend, some short-term technical indicators suggest the stock may be **oversold** or in a "short term typical pullback" favoring long trades, but it is also in a "Strong Down trend (1 month)."

4.  **Major Price Drop (Disappointing Earnings):** The stock experienced a **significant drop, plummeting by 24%** following a disappointing earnings report in June 2025. This decline highlighted investor disappointment with the financial results, which failed to meet market expectations.

5.  **Major Price Surge (Pre-Market Spike):** The stock **surged by 36.04%** in pre-market trading in August 2025, despite the company reporting significant operating losses. The surge was likely triggered by an S-1 registration filing for an equity offering and the company's mention of a broad patent portfolio covering exosome and viral treatments.

6.  **Underlying Corporate Driver:** Aethlon Medical's stock volatility is often linked to updates regarding its core product, the **Hemopurifier®**, a clinical-stage immunotherapeutic device. Early clinical observations from an Australian oncology trial have shown promising directional changes in certain cancer-related biomarkers, which has provided occasional positive momentum.

7.  **High Volatility and Risk:** The stock is considered "very high risk" due to its propensity to move "very much during the day" and with periodic low trading volume.

---

## Long Thesis

Aethlon's future success depends entirely on its unique blood-cleaning device, the Hemopurifier. The bull case assumes that this device successfully proves it can safely and effectively remove harmful elements (like cancer particles and viruses) from a patient's bloodstream, unlocking two massive markets: advanced cancer treatment and chronic viral conditions like Long COVID. Near-term momentum is driven by positive early data from overseas cancer trials and strict cost-cutting measures that stabilize the company's finances. Long-term, if the device gains rapid regulatory approval (aided by its special 'Breakthrough Device' status), the company will transition into a profitable, high-margin business selling disposable treatment cartridges ('razor-and-blade' model) to hospitals worldwide, turning its decades of research into sustained shareholder wealth.

---

## Long Thesis Assumptions

The entire investment relies on these 'if' statements: 1) The ongoing human clinical trials (especially the Australian cancer trial) must conclusively prove that the Hemopurifier is safe and, critically, that it works (efficacy). 2) The company must secure the large amounts of funding or strategic partnerships needed to complete the expensive remaining trials. 3) Regulatory agencies like the FDA must grant final approval for the device's use in cancer and/or viral indications, validating its special 'Breakthrough' status. 4) No competitor emerges with a cheaper or more effective drug or therapy that makes the physical device obsolete before it is commercialized.

---

## Bear Case Scenario

The long thesis for Aethlon Medical, Inc. (AEMD) contains significant flaws related to clinical trial stage, financial sustainability, and competitive threats, which are disguised by over-optimistic interpretation of early-stage data and regulatory status.

### **Bear Case Thesis: Critique and Flaws**

1.  **Premature Efficacy Claims from an Early-Stage Trial:** The "positive early data" is from a small, Phase 1-like **Early Feasibility Study (EFS)** in Australia focused on **safety, feasibility, and dose-finding**, not clinical efficacy. The company's own preliminary data release explicitly cautioned that changes in biomarkers should **not be interpreted as evidence of clinical benefit** or correlated with clinical efficacy.
2.  **Severe and Constant Financial Strain and Shareholder Dilution:** The assumption of "stabilized company's finances" is fragile. As of June 30, 2025, the company reported a tight cash balance of approximately **$3.8 million** and a quarterly operating loss of $1.8 million, indicating a very limited cash runway. The funding required to complete the "expensive remaining trials" (Phase 2, 3, and a Premarket Approval/PMA trial) is being secured through frequent and **highly dilutive public offerings** (e.g., the $4.5 million offering in September 2025 of common stock and warrants), which consistently erode existing shareholder value.
3.  **Regulatory Headwinds Despite "Breakthrough Device" Status:** The FDA's "Breakthrough Device" designation, received back in **2018**, only facilitates development and priority review; it is not a guarantee of "rapid regulatory approval." The device still requires a large, expensive Premarket Approval (PMA) trial to definitively prove clinical efficacy, a critical and costly hurdle that remains years away from completion.
4.  **Obsolete Device Risk in a Fast-Moving Therapeutic Market:** The Long COVID market is being aggressively pursued by pharmaceutical companies developing **cheaper, logistically simpler drug-based immunomodulators** (e.g., low-dose Naltrexone and baricitinib, the latter being in federally-funded Phase 3 trials), which could render an expensive, invasive, and complex **extracorporeal blood purification device** commercially obsolete for a chronic condition before it even reaches market.
5.  **Direct Competition in Blood Purification and Exosome Targeting:** The Hemopurifier faces competition from other established blood purification platforms (e.g., Seraph 100, CytoSorb) that have already received FDA Emergency Use Authorizations (EUAs) for critical care indications like COVID-19. Furthermore, its core technology of exosome-targeting is a major field with rival innovations focused on microfluidic chips and engineered exosome drug delivery systems, posing a threat of a more efficient or less invasive therapy emerging.
6.  **Unproven Commercial Model:** The "razor-and-blade" model (selling the device and disposable cartridges) is speculative, as the entire market rests on the device achieving **unprecedented, large-scale commercial efficacy** in two massive, distinct, and highly competitive disease states (advanced cancer and Long COVID), an outcome that is far from certain given its current clinical stage.

---

## Next Steps

Based on your comprehensive analysis, the company's financial and regulatory environment is extremely dynamic. The most critical questions remain focused on liquidity and the transition of the flagship device from a research concept to a commercially viable product.

Here are the most important next steps and questions left unanswered for your investigation, particularly in light of the November 12, 2025, fiscal Q2 2026 earnings report.

***

### Next Steps & Key Unanswered Questions

#### **I. Financial and Dilution Risk (The Immediate Threat)**

1.  **Analyze the Post-Reverse Split Capital Structure:**
    *   **Question:** What is the precise number of shares outstanding *after* the 1-for-10 reverse stock split (effective October 2025) and the 5-million-unit offering (September 2025)?
    *   **Goal:** Calculate the current, accurate market capitalization. The reverse split artificially boosts the price per share but does not remove the threat of dilution from the 5 million new shares issued and the 5 million *immediately exercisable warrants* at a low strike price of **\$0.90**.

2.  **Evaluate Management's New Cash Runway Guidance:**
    *   **Question:** What is the *current* explicit cash runway projection given in the November 12, 2025, Q2 2026 financial report?
    *   **Goal:** The Q1 2026 report stated "substantial doubt about the Company's ability to continue as a going concern." Determine if the subsequent **\$3.9 million (net)** capital raise alleviated this "going concern" risk or simply pushed the problem a few quarters forward.

3.  **Investigate Executive Compensation vs. Dilution:**
    *   **Question:** Does the recent reverse split trigger an automatic adjustment (resetting) of the stock and option awards for the CEO and board, and how does the recent *increase* in CEO compensation compare to the *magnitude* of shareholder dilution over the last year?
    *   **Goal:** Assess management's incentive alignment. If a high fixed salary and adjusted equity awards are maintained despite extreme shareholder value destruction (dilution/split), the risk of misaligned incentives is validated.

#### **II. Clinical Development & Strategic Partnerships (The Long-Term Thesis)**

4.  **Confirm the Long COVID Clinical Trial Plan:**
    *   **Question:** Has Aethlon filed an Investigational Device Exemption (IDE) or an Investigator-Initiated Trial (IIT) for a Long COVID clinical study, or what is the projected timeline for the first human Long COVID trial?
    *   **Goal:** Move the Long COVID catalyst from a theoretical IP-driven argument to a concrete, time-bound clinical event. Without a trial plan, the new Long COVID patents remain purely speculative long-term assets.

5.  **Search for Major Strategic Funding or Commercial Partnerships:**
    *   **Question:** Are there any *recent* public announcements or analyst questions regarding major non-dilutive funding, such as a new government grant (e.g., DARPA/BARDA), a commercial licensing deal, or a large-scale strategic investment (outside of retail public offerings)?
    *   **Goal:** A small-cap R&D company cannot fund late-stage, multi-million-dollar Phase 3 trials on its own. The entire long thesis hinges on a third-party partner validating and financing the Hemopurifier's clinical future.

6.  **Evaluate Australian Oncology Trial Endpoint Progression:**
    *   **Question:** What is the specific timeline for the Data Safety Monitoring Board (DSMB) review of the second cohort in the Australian oncology trial, and when is *clinical efficacy* data (not just biomarker changes) expected to be released?
    *   **Goal:** Differentiate between "encouraging biomarker observations" (Phase 1/Safety data) and genuine evidence of tumor response or overall survival (Efficacy data, which is needed for the next phase).